Potent and bioavailable irreversible inactivator of PAD4

Nonsteroidal anti-inflammatory drug (NSAID)

Inhibitor of neutrophil superoxide production

Novel FAP-targeted Fluorescein dye conjugate

Novel FAP-targeted NIR dye conjugate

Inducer of apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers

Stable and persistent PKC activator

Novel folate-caged pomalidomide-based anaplastic lymphoma kinase (ALK) PROTAC, effectively degrading ALK fusion proteins in cancer cells in a FOLR1-dependent manner

Novel inhibitor of C. difficile's FASII pathway

Novel potent and specific fatty acid synthase (FASN) inhibitor

Novel fatty acid synthase (FASN)

Novel folate-targeted TLR7 agonist, selectively accumulating in profibrotic macrophages and suppressing fibrosis-inducing cytokine production, reprograming M2-like fibrosis-inducing macrophages into fibrosis-suppressing macrophages, resulting in dramatic

Dopamine D4 receptor antagonist

Novel irreversible dopamine D2 receptor ligand, covalently binding the L94C mutant of the dopamine D2 receptor

Dopamine D4 receptor antagonist

Highly potent and selective dopamine D4 receptor agonist

Potent and selective dopamine D3 receptor partial agonist

First-in-class covalent allosteric inhibitor of fructose-1,6-bisphosphate aldolase (FBA) from Candida albicans (CaFBA)

Novel potent αvβ3 antagonist. reducing GBM tumor growth and viability by up to 98%

Novel CAIX inhibitor, inhibiting breast cancer invasion and metastasis

Specific inhibitor of inflammasome assembly, targeting the NLRP3 inflammasome by interfering with the proximity-induced autocleavage of procaspase-1

Novel phosphodiesterase 4 (PDE4) inhibitor with little emetic potential, blocking MPP+ induced oxidative damage in SH-SY5Y cells and neurons via AMPK-dependent autophagy